Haloperidol is one of the oldest drugs still being used today. It is mainly prescribed for the treatment of delirium, schizophrenia, manic phase of bipolar disorder, and acute psychomotor agitation. Haloperidol was introduced as an antipsychotic and anti-emetic compound by Janssen Pharmaceutica, Belgium, in 1957. Twenty-two years later, the first clinical case was published connecting the sudden demise of a 35-year-old woman to acute treatment with haloperidol (no details on QT interval or arrhythmia were provided) [@b0005]. Since then various studies reported the association between haloperidol and the increased risk of ventricular tachyarrhythmias and sudden cardiac death (SCD), see [Table 1](#t0005){ref-type="table"}. In general, elevated arrhythmia susceptibility was only accompanied by mild QTc prolongation [@b0010], [@b0015], [@b0020], but examples of severe QTc prolongation [@b0025], [@b0030] or its overt absence are available in the literature [@b0035], [@b0040]. In one case-cross over study [@b0045] that accounted for the SCD risk associated with schizophrenia itself [@b0050], the risk of SCD related to haloperidol remained significantly elevated. Especially patients in whom treatment lasted only shortly (\<28 days), the risk of SCD was higher [@b0045].Table 1Studies and case reports on relation between haloperidol and arrhythmia susceptibility.Ref.YearType of studyNr. of patientsAdministrationDuration of treatmentQTc (ms)QT risk factorCardiac disease/structural abnormalities(Risk of) arrhythmiasKetai [@b0005]1979Case1Intravenous4 daysN.A.Female genderN.A.SCDKriwisky [@b0025]1990Case1Oral7 days720NoMitral-valve prolapseTdPDouglas [@b0030]2000Case series3Intravenous2--5 days509--648NoAcute coronary syndrome (day 2--13), ischemic cardiomyopathyVF (1 case), no arrhythmia (2 cases)Perrault [@b0035]2000Case1Intravenous3 days413Female genderPost coronary bypass surgery, moderate LV dysfunctionPremature ventricular complexes, R-on-T, TdPHatta [@b0015]2001Cross-sectional cohort307IntravenousN.A.454Hypokalemia (47%)Not specifiedNo arrhythmiasRay [@b0055]2001Cohort481,744Haloperidol in 21%N.A.N.A.N.A.CV disease score:\
if diagnosed or treated for cardiovascular disease, including medications, outpatient encounters, or hospitalizationsSCD risk (no CV disease): 2.4 (95% C.I. 1.8--3.2)\
SCD risk (severe CV disease): 3.5 (95% C.I. 1.7--7.5)Remijnse [@b0060]2002Case1OralSingle460 prior to haloperidolHypokalemia, hypomagnesemiaAlcoholic cardiomyopathySCDHennessy [@b0010]2002Cohort41,295Oral30 daysN.A.N.A.N.A.Cardiac arrest/ventricular arrhythmias:4.2 (95% C.I. 3.5--5.0) per 1000 person yearsAkers [@b0065]2004Case1Intravenous5 days533LevofloxacinPneumoniaTdPBush [@b0020]2008Cases57Oral or intravenous3 days+ 9.8 (95% C.I. 0.6--19.0)28% had ≥ 1 other QT-prolonging drug; 25% electrolyte abnormalitiesCongestive heart failure (12%), cardiomyopathy (6%), ischemic heart disease (18%)No arrhythmiasJolly [@b0070]2009Case-control1010 cases; 3030 controlsOralN.A.N.A.Hypokalemia (3%), hypocalcemia (1%), bradycardia/AV block (2%)Previous myocardial infarction (11%), heart failure (10%),SCD:\
+ CV disease: 7.8 (95% C.I. 0.8--72.8)\
− CV disease: 2.6 (95% C.I. 0.1--48.3)Ginwalla [@b0075]2009Case1IntravenousSingle injectionN.A.Pre-existing QTc prolongation 579 msComplete AV blockTdPMuzyk [@b0080]2012Cohort175IntravenousNot specified\>50% had prolonged QTc before haloperidol86% ≥ 1 risk factor; ≥ 2 in 58%; LQT-prolonging drugs in 43%; electrolyte abnormalities in 30%80% ≥ 1 CV risk factorN.A.Honkola [@b0085]2012Case-control1814 (SCD), 1171 (AMI)OralN.A.N.A.N.A.Acute coronary syndromeSCD risk\
Antipsych.: 4.4 (95% C.I. 2.9--6.6)\
Antipsych. + antidepressant 5.1 (95% C.I. 2.2--11.2)Wu [@b0045]2015Case-cross over17,718OralHigh risk \<28 daysN.A.Adjusted for risk factorsNo modifierSCD/ventricular arrhythmia: 1.5 (95% C.I. 1.2--1.8)Salvo [@b0090]2016Meta-analysis740,306 person-years and\
2557 cases, 17,670 controlsN.A.N.A.N.A.Mean hERG blockade potencyN.A.SCD risk haloperidol:\
3.0 (95% C.I. 1.6--5.5)Naksuk [@b0040]2017Prospective, observational244Not specified1.0--10.0454 ± 49N.A.Acute coronary syndrome (61%), heart failure (65%)No difference for in-hospital mortality, ventricular arrythmias of 1-year mortality[^1]

The metabolism of haloperidol is complex. It is degraded by CYP3A4 activity, with lesser contributions by 2D6 [@b0095]. Some of haloperidol's metabolites inhibit 2D6, affecting other drug levels. Haloperidol can contribute to increased anticholinergic and central nervous system depressant effects of opiates, anesthetics, and alcohol. Multiple drugs interact with haloperidol [@b0100]. Haloperidol acts as a nonspecific drug with affinity to dopamine D~2~ receptors, serotonin 5HT~2~ receptors, α~1~-adrenergic receptors, σ~1~/σ~2~ receptors, and muscarinic M~1~ receptors. Besides these neural modulatory pathways, haloperidol blocks the rapidly-activating delayed-rectifier potassium current (I~Kr~), a major contributor to cardiac repolarization [@b0105], [@b0110]. In rat retinal ganglion cells [@b0115] and Xenopus oocytes expressing hERG channels [@b0120], the slowly-activating delayed-rectifier I~Ks~ (-like) is inhibited by this antipsychotic drug by a limited degree. Haloperidol exerts minor effects on the arrhythmogenic late sodium current [@b0125]. Moreover, via stimulation of σ~2~ receptors, haloperidol is involved in additional inhibition of the hERG potassium current [@b0130] and transient outward potassium current [@b0135]. Acute and chronic exposure to haloperidol results in increased QT intervals in rats [@b0140], guinea pigs [@b0140], [@b0145], and rabbits [@b0150]. In isolated rabbit hearts, it led to a marked increase in spatiotemporal dispersion of repolarization, early afterdepolarizations, and polymorphic ventricular tachycardia [@b0155].

An elevated arrhythmia risk during an acute coronary event in the presence of antipsychotic drug therapy, including haloperidol, has been suggested by Honkola et al [@b0085]. Here, the treatment with antipsychotic drugs was paralleled by a significant and independent risk factor for the occurrence of SCD (odds ratio 3.4, 95% C.I. 1.8--6.5, *P* \< 0.001). This risk was even more evident when phenothiazines or any other antidepressants were co-administered (odds ratio 18.3, 95% C.I. 2.5--135.2, *P* \< 0.001). The latter study constitutes one of the few in which investigators focused on the risk of haloperidol in acute ischemia/infarction.

In this issue of the journal; *IJC Heart & Vasculature*, [@b9000] Sattler and coworkers postulate that the surplus mortality observed in patients with psychiatric illnesses treated with haloperidol could be explained by a higher incidence of acute myocardial infarction-related ventricular tachyarrhythmia including ventricular fibrillation (VF) and torsades de pointes (TdP). In their pig model of mid-LAD occlusion, Sattler observed primary VF in 64% of the control animals, compared to 27 and 33% (within 30 min) in the low and high haloperidol treatment arms, respectively. Catecholamine-sensitive phase-1b arrhythmias were less present in the high-dose haloperidol group. This observation seems counterintuitive at first glance as it occurred despite significant global QTc prolongation and dispersion of repolarization prior to, during and after the ischemic trigger. However, ischemia-induced changes of the myocardium, largely driven by an increase in extracellular potassium concentration and elevated sympathetic input, result in regional depolarization of the resting membrane potential, slowed conduction, and action-potential shortening. It could be hypothesized that haloperidol's inhibitory effects on I~Kr~, and to a lesser extent on I~Ks~, may have counterbalanced local repolarization heterogeneities, thus exerting some antiarrhythmic action. The latter is supported by the observation by Sattler [@b9000] et al that phase-1b ectopy was suppressed. Besides, the authors report a reduced dominant frequency of VF in the presence of haloperidol suggesting prolongation of ventricular repolarization, slowed cardiac conduction properties, or a combination of both. An increased threshold for the induction of VF was also observed in a healthy pig model pretreated with haloperidol [@b0160]. Similar to the findings by Sattler, intracardiac conduction velocity was reduced during intravenous haloperidol infusion in an anesthetized guinea pig model [@b0165]. As potential explanation, one may consider the pleiomorphic effects that haloperidol has on various receptors. Haloperidol-related σ~1~/σ~2~ receptor stimulation concurrently modulates various cardiac voltage-gated potassium, calcium, but also sodium channels, significantly reducing the I~Na~ in HEK-293 cells, COS-7 cells, and neonatal mouse cardiac myocytes [@b0170]. The slower heart rates during the high-dose regimen may be indicative of the indirect ionic effects brought about by σ1/σ2 receptors stimulation.

The authors are to be complimented for their comprehensive approach to investigate proarrhythmic side-effects of haloperidol taking both electrics and mechanics into account in their intact pig model. Most contemporary arrhythmia studies still focus merely on electrical denominators of arrhythmogenesis, despite the increasing recognition of the importance of mechano-electric and autonomic triggers/modulators of arrhythmia. This holds true for acquired arrhythmia syndromes, and particularly when studying prolonged-repolarization ventricular tachyarrhythmias like TdP. Both in long-QT syndrome patients and in a drug-induced LQTS dog model, electromechanical heterogeneities and a negative electromechanical window (defined as timeframe between end of contraction minus end of repolarization) consistently preluded these deadly events [@b0175], [@b0180]. While the (mini)pig has a high susceptibility to the development of VF, it appeared refractory to torsades-de-pointes arrhythmias despite extensive QT prolongation [@b0185]. As clinical documentation of the type of life-threatening arrhythmias in patients with haloperidol during an acute ischemic event is currently lacking, we are left in the dark as to the underlying arrhythmic mechanisms: primary VF or TdP/polymorphic ventricular tachycardia precipitating VF. Conversely, it is well-known that patients who develop QT prolongation in the subacute phase after myocardial infarction (day 2--11) are more prone to deadly arrhythmias [@b0190]. Treatment with haloperidol during such electromechanical and autonomic dynamic phase can easily aggravate patient's arrhythmia susceptibility.

In conclusion, this comprehensive report by Sattler further adds to our understanding of the complex actions of haloperidol on the arrhythmogenic substrate and triggers in the setting of an acute myocardial infarction. The observation that haloperidol is associated with less phase-1b premature ventricular complexes in the presence of obvious global QT prolongation renders the important insights that this multifaceted drug may stabilize the arrhythmogenic substrate under specific conditions and that global repolarization abnormalities may not suffice for arrhythmia induction. Extending to this, it remains to be determined by mechanistic studies whether haloperidol harbors torsadogenic potency in the *sub*acute phase of myocardial infarction (days to weeks after coronary occlusion; when spontaneous QT prolongation is frequently observed), and which determinants aggravate arrhythmia susceptibility in individual patients, as the diversity in arrhythmia responses is significant.

[^1]: AMI indicates acute myocardial infarction; antipsych., antipsychotic; AV, atrioventricular; C.I., confidence interval; CV, cardiovascular; LQT, long QT; N.A., not available; SCD, sudden cardiac death; TdP, torsades de pointes; VF, ventricular fibrillation.
